Drug Dependence
Conditions
Keywords
opioid dependence, methadone, opioid
Brief summary
This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the subject's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e.g., heart rate, blood pressure, respiration rate) and behavior. Each subject will receive 2-4 of the listed interventions.
Interventions
DRUGCycloserine
Cycloserine: 500, 675, 750 mg oral capsule may possibly be given
DRUGDiltiazem
Diltiazem: 30, 60, 120 mg oral capsule may possibly be
DRUGGabapentin
Gabapentin: 100, 200, 400 mg oral capsule may possibly be given
DRUGIsradipine
Isradipine: 5, 10 mg oral capsule may possibly be given
DRUGNaloxone
Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given
DRUGNifedipine
Nifedipine: 5, 10, 20 mg oral capsule may possibly be given
DRUGPlacebo
Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
DEVICESaline
Saline: I.M. injection may possibly be given
DRUGVerapamil
Verapamil: 30, 60, 120 mg oral capsule may possibly be given
Sponsors
University of Arkansas
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Must be between the ages of 18-65. 2. Participation in the UAMS Substance Abuse Treatment Clinic Methadone Maintenance Program or the CATAR Clinic Little Rock with maintenance on a stable dose of methadone (+ or - 10 mg) for at least 1 month prior to study entry. 3. Subjects would have to be in good standing in the methadone maintenance program in order to participate; i.e., compliance with scheduled medication and group therapy session hours. This would be defined as \< 3 missed methadone medications and missed \< 3 group or \<3 individual therapy sessions in the two months prior to study participation 4. Subjects must submit a urine sample negative for illicit drugs prior to study entry. 5. Subjects must be able to read and understand English.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Drug Discrimination Measure | Every session |
Secondary
| Measure | Time frame |
|---|---|
| Self-reported effects | Every Session |
| Vital Signs | Every session |
Countries
United States
Outcome results
None listed